How Specials Can Deliver Value to the NHS | Page 15

The MHRA has clearly directed that all immunosuppressant products relating
to this case study should be supplied as brands so that the bioavailability
is consistent18. Prescribers should prescribe the oral immunosuppressant
products by brand only19. Changing preparations may impact on symptom
control and result in adverse events. In addition, it is important to minimise,
wherever possible, administration error risks. Pharmacists should always
dispense the exact brand prescribed19. They should contact the prescriber if
the prescription is not clear to ensure the appropriate medicine is dispensed18
or if the patient/carer mentions an unexpected change in their medication.
Please also refer to Assessing clinical need on page 6.

Cost-effectiveness